AR130984A1 - Compuestos novedosos - Google Patents

Compuestos novedosos

Info

Publication number
AR130984A1
AR130984A1 ARP230102982A ARP230102982A AR130984A1 AR 130984 A1 AR130984 A1 AR 130984A1 AR P230102982 A ARP230102982 A AR P230102982A AR P230102982 A ARP230102982 A AR P230102982A AR 130984 A1 AR130984 A1 AR 130984A1
Authority
AR
Argentina
Prior art keywords
novel compounds
compounds
novel
methods
general formula
Prior art date
Application number
ARP230102982A
Other languages
English (en)
Inventor
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina Mesch
Jonathan Martin Shannon
Sandra Steiner
Andreas Michael Tosstorf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR130984A1 publication Critical patent/AR130984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general (1) en donde R¹, R², R³, R⁴ y R⁵ son como se describe en la presente, composición que incluye los compuestos y métodos para usar los compuestos.
ARP230102982A 2022-11-09 2023-11-07 Compuestos novedosos AR130984A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22206271 2022-11-09

Publications (1)

Publication Number Publication Date
AR130984A1 true AR130984A1 (es) 2025-02-05

Family

ID=84330531

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102982A AR130984A1 (es) 2022-11-09 2023-11-07 Compuestos novedosos

Country Status (15)

Country Link
EP (1) EP4615841A1 (es)
JP (1) JP2025539252A (es)
KR (1) KR20250103639A (es)
CN (1) CN120187721A (es)
AR (1) AR130984A1 (es)
AU (1) AU2023376398A1 (es)
CA (1) CA3268380A1 (es)
CL (1) CL2025001372A1 (es)
CO (1) CO2025005518A2 (es)
CR (1) CR20250185A (es)
IL (1) IL319011A (es)
MX (1) MX2025004959A (es)
PE (1) PE20251696A1 (es)
TW (1) TW202434581A (es)
WO (1) WO2024099992A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
JP2026509587A (ja) * 2023-03-23 2026-03-19 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 トリアジン化合物およびその使用
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2025261430A1 (zh) * 2024-06-21 2025-12-26 成都赜灵生物医药科技有限公司 苯并噻吩类氘代化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021219784A1 (en) * 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv New triazinoindole compounds

Also Published As

Publication number Publication date
IL319011A (en) 2025-04-01
WO2024099992A1 (en) 2024-05-16
MX2025004959A (es) 2025-06-02
JP2025539252A (ja) 2025-12-04
PE20251696A1 (es) 2025-07-02
TW202434581A (zh) 2024-09-01
CO2025005518A2 (es) 2025-05-19
AU2023376398A1 (en) 2025-02-13
KR20250103639A (ko) 2025-07-07
CL2025001372A1 (es) 2025-06-23
CA3268380A1 (en) 2024-05-16
CR20250185A (es) 2025-06-10
CN120187721A (zh) 2025-06-20
EP4615841A1 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
AR131006A1 (es) Compuestos novedosos
AR123424A1 (es) Nuevos compuestos heterocíclicos
AR131278A1 (es) Compuestos novedosos
AR131282A1 (es) Compuestos novedosos
AR132340A1 (es) Compuestos tricíclicos para el tratamiento de cáncer
CL2023003154A1 (es) Compuestos heterocíclicos
CL2024004085A1 (es) Compuestos macrocíclicos inhibidores de kras, uso para tratar cáncer.
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
AR132377A1 (es) Compuestos novedosos
CO2025001184A2 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CL2023003312A1 (es) Inhibidores de nlrp3
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
AR116283A1 (es) Inhibidores del sarcómero cardíaco
CR20220116A (es) Compuestos heterocíclicos
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CL2025001372A1 (es) Derivados de triazinona como inhibidores de nlrp3.
AR132456A1 (es) Compuestos novedosos
AR132992A1 (es) Agonistas de trem2
CO2025008956A2 (es) Inhibidores de polq
CL2025000126A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
CO2025003256A2 (es) Derivados novedosos deuterados de pirimidin-2-il sulfonamida
CO2025002033A2 (es) Derivados novedosos de indol sulfonamida 7 sustituidos
CO2022012773A2 (es) Moduladores de nampt
AR133375A1 (es) Compuestos novedosos
AR131633A1 (es) Derivados novedosos de pirimidinil sulfonamida